Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: A position statement

Claudio Marcassa, Jeroen J. Bax, Frank Bengel, Birger Hesse, Claus L. Petersen, Eliana Reyes, Richard Underwood

Research output: Contribution to journalArticle

Abstract

Mortality rates due to coronary artery disease (CAD) have declined in recent years as result of improved prevention, diagnosis, and management. Nonetheless, CAD remains the leading cause of death worldwide with most casualties expected to occur in developing nations. Myocardial perfusion scintigraphy (MPS) provides a highly cost-effective tool for the early detection of obstructive CAD in symptomatic individuals and contributes substantially to stratification of patients according to their risk of cardiac death or nonfatal myocardial infarction. MPS also provides valuable information that assists clinical decision-making with regard to medical treatment and intervention. A large body of evidence supports the current applications of MPS, which has become integral to several guidelines for clinical practice.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalEuropean Heart Journal
Volume29
Issue number4
DOIs
StatePublished - Feb 2008

    Fingerprint

Keywords

  • Coronary artery disease
  • Cost-effectiveness
  • Myocardial perfusion scintigraphy
  • Radionuclide
  • Scintigraphy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Marcassa, C., Bax, J. J., Bengel, F., Hesse, B., Petersen, C. L., Reyes, E., & Underwood, R. (2008). Clinical value, cost-effectiveness, and safety of myocardial perfusion scintigraphy: A position statement. European Heart Journal, 29(4), 557-563. https://doi.org/10.1093/eurheartj/ehm607